MPR4h
FDA to Review Resubmitted BLA for Ophthalmic Bevacizumab for Wet AMD
The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
(Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of ...